Log in

NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Forecast & News

$3.59
+0.08 (+2.28 %)
(As of 02/21/2020 07:06 AM ET)
Today's Range
$3.42
Now: $3.59
$3.63
50-Day Range
$3.36
MA: $3.69
$4.29
52-Week Range
$2.66
Now: $3.59
$7.39
Volume349,222 shs
Average Volume502,468 shs
Market Capitalization$119.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT
CUSIP89354M10
Phone617-807-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.12 million
Book Value$1.48 per share

Profitability

Net Income$-112,360,000.00
Net Margins-505.07%

Miscellaneous

Employees101
Market Cap$119.51 million
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.


Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.06) by $0.06. The specialty pharmaceutical company earned $3.93 million during the quarter, compared to analysts' expectations of $3.63 million. Paratek Pharmaceuticals had a negative net margin of 505.07% and a negative return on equity of 5,327.73%. View Paratek Pharmaceuticals' Earnings History.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Paratek Pharmaceuticals.

How can I listen to Paratek Pharmaceuticals' earnings call?

Paratek Pharmaceuticals will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for PRTK?

7 Wall Street analysts have issued 1 year price targets for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $17.33 in the next year. This suggests a possible upside of 382.8% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals.

What is the consensus analysts' recommendation for Paratek Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals.

What are Wall Street analysts saying about Paratek Pharmaceuticals stock?

Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (2/20/2020)
  • 2. HC Wainwright analysts commented, "We view the promotion of Dr. Loh as particularly well-deserved and quite likely to be broadly well-received by investors and other constituents. Affirm Buy." (6/26/2019)

Has Paratek Pharmaceuticals been receiving favorable news coverage?

Press coverage about PRTK stock has been trending negative this week, InfoTrie reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Paratek Pharmaceuticals.

Are investors shorting Paratek Pharmaceuticals?

Paratek Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 7,770,000 shares, a decline of 5.9% from the January 15th total of 8,260,000 shares. Based on an average daily volume of 1,224,700 shares, the short-interest ratio is currently 6.3 days. Currently, 28.1% of the shares of the stock are short sold. View Paratek Pharmaceuticals' Current Options Chain.

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Exelixis (EXEL), Verastem (VSTM), EXACT Sciences (EXAS), Energy Transfer LP Unit (ET), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO) and Omeros (OMER).

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael F. Bigham, Chairman & CEO (Age 61)
  • Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 57)
  • Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)
  • Mr. Douglas W. Pagán, Consultant (Age 47)

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (2.04%), General American Investors Co. Inc. (1.94%), ICM Asset Management Inc. WA (1.35%), Water Island Capital LLC (1.26%), Goldman Sachs Group Inc. (1.03%) and Roumell Asset Management LLC (1.02%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Which major investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including Roumell Asset Management LLC, General American Investors Co. Inc., J. Goldman & Co LP, Trellus Management Company LLC, Water Island Capital LLC and Raymond James & Associates. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Randall B Brenner and William M Haskel. View Insider Buying and Selling for Paratek Pharmaceuticals.

Which major investors are buying Paratek Pharmaceuticals stock?

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., ICM Asset Management Inc. WA, Smith Asset Management Group LP, Banco Bilbao Vizcaya Argentaria S.A., Stifel Financial Corp, Oxford Asset Management LLP, Marshall Wace LLP and New York State Common Retirement Fund. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $3.59.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $119.51 million and generates $17.12 million in revenue each year. The specialty pharmaceutical company earns $-112,360,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.View Additional Information About Paratek Pharmaceuticals.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com/.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]


MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  354 (Vote Underperform)
Total Votes:  747
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Balanced Fund

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel